Revolution's RAS inhibitor may be approved in an all-comer population, but molecular profiling remains key to treatment ...

The firm said it will stop enrolling a late-stage trial in blood cancers to prioritize a preclinical in vivo T-cell receptor program in solid tumors.

BioNTech and Roche subsidiary Genentech are discontinuing testing of their jointly developed personalized cancer vaccine in colorectal cancer patients. The companies were testing the mRNA vaccine ...

Sangrail Biologics is already discussing with the FDA a regulatory path for the gene therapy that Abeona Therapeutics dropped ...

University of Toronto researchers are betting yes, pointing to tRNA's ease of administration and efficacy advantages over ...

For patients with microsatellite instability of mismatch repair deficiency, the final decision cements access to the drug, which was previously offered provisionally.

The approval was based on results from the Phase III HERIZON-GEA-01 trial, which compared the two Ziihera combos to Herceptin plus chemo.

The firm will evaluate the molecular glue degrader MRT-2359 with J&J's Erleada in 25 patients with heavily pretreated AR mutation-positive prostate cancer.

The firm is testing the next dose level of RV-01 in a Phase I/IIa study after clearance from a safety and monitoring committee.

The hospital, which has been making investments into precision medicine, inked a multi-phase deal to integrate PGx into clinical workflows.

The firm hopes to expand Revtorpyk's approval to HR-positive, HER2-negative breast cancer patients regardless of PIK3CA status.